-
Recent Posts
Recent Comments
- MichaelOrdman on Fighting over Israeli engineers
- Elaine Morales on Fighting over Israeli engineers
- MichaelOrdman on Enriched seaweed can feed the world
- Professor Rajan Rajan on Enriched seaweed can feed the world
- MichaelOrdman on Fast glaucoma treatment in trials
Archives
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- July 2010
Categories
Meta
Search Results for: gamida
More approvals on the way
This article identifies three more Israeli companies that are expected to receive FDA approval for treatments in 2023. They are Gamida Cell (Omidubicel / NiCord – bone marrow transplants); Protalix (PRX-102 – Fabry disease); and BioLineRX (BL-8040 / Motixafortide – … Continue reading
Posted in Israel's Medical Achievements
Leave a comment
Investment in Israeli startups 28/2/21
CYE raised $120 million; Gamida Cell raised $75 million; Personetics raised $75 million; Pliops raised $65 million; PerimeterX raised $57 million; Lusha raised $40 million; Redefine Meat raised $29 million; Atera raised $25 million; Nanit raised $25 million; EquityBee raised … Continue reading
Posted in Economy & Business
Leave a comment
Blood cancer treatment trial succeeds
Israel’s Gamida Cell (reported here previously) published the results of its Phase 3 trial of omidubicel (previously NiCord) in blood-based cancer patients. The treatment resulted in faster blood count recovery, fewer bacterial and viral infections, and fewer days in the … Continue reading
Posted in Israel's Medical Achievements
Leave a comment
Good news for bone-marrow transplants
Israeli biotech Gamida Cell (see here) published positive results in its Phase 3, 50-center trial of NiCord (now called Omidubicel) that aims to increase the success of bone marrow transplants in blood cancer patients. The stem cells were established much … Continue reading
Posted in Israel's Medical Achievements
Leave a comment
Success in Sickle-Cell Disease trial
Israeli biotech Gamida Cell published positive results in its Phase I/II trial of NiCord, for the treatment of Sickle-Cell Disease (SCD). All the patients that completed the trial were free of SCD symptoms. http://www.globes.co.il/en/article-gamida-reports-positive-nicord-results-1001165382
Posted in Israel's Medical Achievements
Leave a comment
Treatment for Sickle Cell Disease
The first patient with Sickle Cell Disease (SCD) has received a transplant of CordIn from Israeli biotech Gamida Cell. CordIn is an alternative for patients awaiting a suitable match for bone marrow transplants. Trials of CordIn are planned for patients … Continue reading
Posted in Israel's Medical Achievements
Leave a comment
Blood cancer treatment success
Israel’s Gamida Cell reported good results from Duke University trials of its NiCord blood cancer treatment. Compared with 101 patients receiving ordinary umbilical cord blood, the 18 patients using NiCord had a lower mortality rate, less infections and less time … Continue reading
Posted in Israel's Medical Achievements
Leave a comment
Global demand for Israeli health tech
Multinationals have recently been investing heavily in Israeli life science companies. They include Boston Scientific into MValve (heart valves), Novartis into Gamida Cell (stem cell therapies) and eHealthVentures into Intendu (brain dysfunction treatment). http://www.starterincubator.com/venture-capital/israeli-health-tech-is-heating-up-with-a-wave-of-interest-from-abroad/
Posted in Economy & Business
Leave a comment
Leukemia treatment gets boost
The US FDA and the European Medicines Agency have awarded Israel’s stem cell therapy developer Gamida Cell orphan status for its NiCord leukemia treatment. NiCord treats acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin lymphoma and myelodysplastic syndrome. http://www.globes.co.il/en/article-gamida-cell-leukemia-treatment-granted-orphan-drug-status-1000998856
Posted in Israel's Medical Achievements
Leave a comment
The world loves Israeli companies
The BDS thugs will not like this. Israel is the 4th most attractive country for foreign direct investment. Recent $multi-million deals include Gamida Cell (by Novartis), Simbionix (by 3D Systems), ClarityRay (by Yahoo), Lamina (by China’s Catalyst CEL) and VidMind … Continue reading
Posted in Economy & Business
Leave a comment